TESTBANK |
LILLEY'S |PHARMACOLOGY |FOR |CANADIAN |HEALTH |CARE |PRACTICE
KARA |SEALOCK
4th Edition
|
TESTBANK |
, lOMoAR | cPSD|
| 3013804
lOMoAR | |
cPSD| 3013804
Chapter 01: Nursing Practice in Canada and Drug Therapy
| | | | | | | |
Sealock: Lilley’s Pharmacology for Canadian Health Care Practice, 4th Edition
| | | | | | | | |
MULTIPLE |CHOICE
1. Which |is |a |judgement |about |a |particular |patient’s |potential |need |or |problem?
a. A |goal
b. An |assessment
c. Subjective |data
d. A |nursing |diagnosis
ANS: | D
Nursing |diagnosis |is |the |phase |of |the |nursing |process |during |which |a |clinical |judgement |is |made |about |how
|conditions |and |life |processes |or |vulnerability |for |that |response.
DIF: Cognitive |Level: |Knowledge
2. The |patient |is |to |receive |oral |furosemide |(Lasix) |every |day; |however, |because |the |patient |is |unable |to |swallo
medication |orally, |as |ordered. |The |nurse |needs |to |contact |the |physician. |What |type |of |problem |is |this?
|
a. A |“right |time” |problem
b. A |“right |dose” |problem
c. A |“right |route” |problem
d. A |“right |medication” |problem
ANS: | C
This |is |a |“right |route” |problem: |the |nurse |cannot |assume |the |route |and |must |clarify |the |route |with |the |p
|time” |problem |because |the |ordered |frequency |has |not |changed. |This |is |not |a |“right |dose” |problem |becau
|inability |to |swallow. |This |is |not |a |“right |medication” |problem |because |the |medication |ordered |will |not |ch
DIF: Cognitive |Level: |Application
3. The |nurse |has |been |monitoring |the |patient’s |progress |on |his |new |drug |regimen |since |the |first |dose |and |has |be
possible |adverse |effects. |What |nursing |process |phase |is |the |nurse |practising?
|
a. Planning
b. Evaluation
c. Implementation
d. Nursing |diagnosis
ANS: | B
Monitoring |the |patient’s |progress |is |part |of |the |evaluation |phase. |Planning, |implementation, |and |nursing |di
|by |this |example.
DIF: Cognitive |Level: |Application
4. The |nurse |is |caring |for |a |patient |who |has |been |newly |diagnosed |with |type |1 |diabetes |mellitus. |Which |statem
outcome |criterion |for |this |patient?
|
a. The |patient |will |follow |instructions.
b. The |patient |will |not |experience |complications.
c. The |patient |adheres |to |the |new |insulin |treatment |regimen.
d. The |patient |demonstrates |safe |insulin |self-administration |technique.
ANS: | D
Having |the |patient |demonstrate |safe |insulin |self-administration |technique |is |a |specific |and |measurable |outc
|instructions |and |avoiding |complications |are |not |specific |criteria. |Adherence |to |the |new |insulin |treatment
|would |be |difficult |to |measure.
DIF: Cognitive |Level: |Application
, lOMoAR | cPSD|
| 3013804
6. The |nurse |is |working |during |a |very |busy |night |shift, |and |the |health |care |provider |has |just |given |the |nurse |a |m
telephone, |but |the |nurse |does |not |recall |the |route. |What |is |the |best |way |for |the |nurse |to |avoid |medication |
|
a. Recopy |the |order |neatly |on |the |order |sheet, |with |the |most |common |route |indicated
b. Consult |with |the |pharmacist |for |clarification |about |the |most |common |route
c. Call |the |health |care |provider |to |clarify |the |route |of |administration
d. Withhold |the |drug |until |the |health |care |provider |visits |the |patient
ANS: |C
If |a |medication |order |does |not |include |the |route, |the |nurse |must |ask |the |health |care |provider |to |clarify |it. |Ne
|administration.
DIF: Cognitive |Level: |Application || |Cognitive |Level: |Analysis
7. Which |constitutes |the |traditional |Five |Rights |of |medication |administration?
a. Right |drug, |right |route, |right |dose, |right |time, |and |right |patient
b. Right |drug, |the |right |effect, |the |right |route, |the |right |time, |and |the |right |patient
c. Right |patient, |right |strength, |right |diagnosis, |right |drug, |and |right |route
d. Right |patient, |right |diagnosis, |right |drug, |right |route, |and |right |time
ANS: |A
The |traditional |Five |Rights |of |medication |administration |were |considered |to |be |Right |drug, |Right |route, |Rig
|Right |patient. |Right |effect, |right |strength, |and |right |diagnosis |are |not |part |of |the |traditional |Five |Rights.
DIF: Cognitive |Level: |Comprehension
8. What |correctly |describes |the |nursing |process?
a. Diagnosing, |planning, |assessing, |implementing, |and |finally |evaluating
b. Assessing, |then |diagnosing, |implementing, |and |ending |with |evaluating
c. A |linear |direction |that |begins |with |assessing |and |continues |through |diagnosing,
|planning, |and |finally |implementing
d. An |ongoing |process |that |begins |with |assessing |and |continues |with |diagnosing,
|planning, |implementing, |and |evaluating
ANS: |D
The |nursing |process |is |an |ongoing, |flexible, |adaptable, |and |adjustable |five-step |process |that |begins |with |ass
|through |diagnosing, |planning, |implementing, |and |finally |evaluating, |which |may |then |lead |back |to |any |of
DIF: Cognitive |Level: |Application
9. When |the |nurse |is |considering |the |timing |of |a |drug |dose, |which |is |most |important |to |assess?
a. The |patient’s |identification
b. The |patient’s |weight
c. The |patient’s |last |meal
d. Any |drug |or |food |allergies
ANS: |C
The |pharmacokinetic |and |pharmacodynamic |properties |of |the |drug |need |to |be |assessed |with |regard |to |any |d
|compatibility |issues. |The |patient’s |identification, |weight, |and |drug |or |food |allergies |are |not |affected |by |th
DIF: Cognitive |Level: |Application
10. The |nurse |is |writing |nursing |diagnoses |for |a |plan |of |care. |Which |reflects |the |correct |format |for |her |nursing
a. Anxiety
b. Anxiety |related |to |new |drug |therapy
c. Anxiety|related |to |anxious |feelings |about |drug |therapy, |as |evidenced |by
|statements |such |as |“I’m |upset |about |having |to |give |myself |shots”
d. Anxiety|related |to |new |drug |therapy, |as |evidenced |by |statements |such |as |“I’m
|upset |about |having |to |give |myself |shots”
ANS: |D
Formulation |of |nursing |diagnoses |is |usually |a |three-step |process. |The |only |complete |answer |is |“Anxiety |r
, lOMoAR | cPSD|
| 3013804
Chapter 02: Pharmacological Principles
| | |
Sealock: Lilley’s Pharmacology for Canadian Health Care Practice, 4th Edition
| | | | | | | | |
MULTIPLE |CHOICE
1. A |patient |is |receiving |two |different |drugs, |which, |at |their |current |dose |forms |and |dosages, |are |both |absorbed
identical |amounts. |Which |term |best |denotes |that |the |drugs |have |the |same |absorption |rates?
|
a. Equivalent
b. Synergistic
c. Compatible
d. Bioequivalent
ANS: | D
Two |drugs |absorbed |into |the |circulation |at |the |same |amount |(in |specific |dosage |forms) |have |the |same |b
|bioequivalent. |“Equivalent” |is |incorrect |because |the |term |“bioavailability” |is |used |to |express |the |extent |o
“Synergistic” |is |incorrect |because |this |term |refers |to |two |drugs |given |together |whose |resulting |effect |is
|effects |of |each |drug |given |alone. |“Compatible” |is |incorrect |because |this |term |is |a |general |term |used |to |ind
|not |have |a |chemical |reaction |when |mixed |(or |given, |in |the |case |of |drugs) |together.
DIF: Cognitive |Level: |Comprehension
2. A |patient |is |receiving |medication |via |intravenous |injection. |Which |information |should |the |nurse |provide |f
a. The |medication |will |cause |fewer |adverse |effects |when |given |intravenously.
b. The |medication |will |be |absorbed |slowly |into |the |tissues |over |time.
c. The |medication’s |action |will |begin |faster |when |given |intravenously.
d. Most |of |the |drug |is |inactivated |by |the |liver |before |it |reaches |the |target |area.
ANS: | C
Intravenous |injections |are |the |fastest |route |of |absorption. |The |intravenous |route |does |not |affect |the |num
|intravenous |route |is |not |a |slow |route |of |absorption, |and |the |intravenous |route |does |not |cause |inactivati
|before |it |reaches |the |target |area.
DIF: Cognitive |Level: |Comprehension
3. Which |is |true |regarding |parenteral |drugs?
a. They |bypass |the |first-pass |effect.
b. They |decrease |blood |flow |to |the |stomach.
c. They |are |altered |by |the |presence |of |food |in |the |stomach.
d. They |exert |their |effects |while |circulating |in |the |bloodstream.
ANS: | A
Drugs |given |by |the |parenteral |route |bypass |the |first-pass |effect, |but |they |still |must |be |absorbed |into |cells |an
|exert |their |effects. |Enteral |drugs |(drugs |taken |orally), |not |parenteral |drugs, |decrease |blood |flow |to |the |sto
|presence |of |food |in |the |stomach. |Parenteral |drugs |must |be |absorbed |into |cells |and |tissues |from |the |circula
|their |effects; |they |do |not |exert |their |effects |while |circulating |in |the |bloodstream.
DIF: Cognitive |Level: |Analysis
4. A |drug’s |half-life |is |best |defined |as
a. The |time |it |takes |for |the |drug |to |elicit |half |its |therapeutic |response.
b. The |time |it |takes |one-half |of |the |original |amount |of |a |drug |to |reach |the |target
|cells.
c. The |time |it |takes |one-half |of |the |original |amount |of |a |drug |to |be |removed |from |the
|body.
d. The |time |it |takes |one-half |of |the |original |amount |of |a |drug |to |be |absorbed |into |the
|circulation.
ANS: | C
A |drug’s |half-life |is |the |time |it |takes |for |one-half |of |the |original |amount |of |a |drug |to |be |removed |from |the |bo
LILLEY'S |PHARMACOLOGY |FOR |CANADIAN |HEALTH |CARE |PRACTICE
KARA |SEALOCK
4th Edition
|
TESTBANK |
, lOMoAR | cPSD|
| 3013804
lOMoAR | |
cPSD| 3013804
Chapter 01: Nursing Practice in Canada and Drug Therapy
| | | | | | | |
Sealock: Lilley’s Pharmacology for Canadian Health Care Practice, 4th Edition
| | | | | | | | |
MULTIPLE |CHOICE
1. Which |is |a |judgement |about |a |particular |patient’s |potential |need |or |problem?
a. A |goal
b. An |assessment
c. Subjective |data
d. A |nursing |diagnosis
ANS: | D
Nursing |diagnosis |is |the |phase |of |the |nursing |process |during |which |a |clinical |judgement |is |made |about |how
|conditions |and |life |processes |or |vulnerability |for |that |response.
DIF: Cognitive |Level: |Knowledge
2. The |patient |is |to |receive |oral |furosemide |(Lasix) |every |day; |however, |because |the |patient |is |unable |to |swallo
medication |orally, |as |ordered. |The |nurse |needs |to |contact |the |physician. |What |type |of |problem |is |this?
|
a. A |“right |time” |problem
b. A |“right |dose” |problem
c. A |“right |route” |problem
d. A |“right |medication” |problem
ANS: | C
This |is |a |“right |route” |problem: |the |nurse |cannot |assume |the |route |and |must |clarify |the |route |with |the |p
|time” |problem |because |the |ordered |frequency |has |not |changed. |This |is |not |a |“right |dose” |problem |becau
|inability |to |swallow. |This |is |not |a |“right |medication” |problem |because |the |medication |ordered |will |not |ch
DIF: Cognitive |Level: |Application
3. The |nurse |has |been |monitoring |the |patient’s |progress |on |his |new |drug |regimen |since |the |first |dose |and |has |be
possible |adverse |effects. |What |nursing |process |phase |is |the |nurse |practising?
|
a. Planning
b. Evaluation
c. Implementation
d. Nursing |diagnosis
ANS: | B
Monitoring |the |patient’s |progress |is |part |of |the |evaluation |phase. |Planning, |implementation, |and |nursing |di
|by |this |example.
DIF: Cognitive |Level: |Application
4. The |nurse |is |caring |for |a |patient |who |has |been |newly |diagnosed |with |type |1 |diabetes |mellitus. |Which |statem
outcome |criterion |for |this |patient?
|
a. The |patient |will |follow |instructions.
b. The |patient |will |not |experience |complications.
c. The |patient |adheres |to |the |new |insulin |treatment |regimen.
d. The |patient |demonstrates |safe |insulin |self-administration |technique.
ANS: | D
Having |the |patient |demonstrate |safe |insulin |self-administration |technique |is |a |specific |and |measurable |outc
|instructions |and |avoiding |complications |are |not |specific |criteria. |Adherence |to |the |new |insulin |treatment
|would |be |difficult |to |measure.
DIF: Cognitive |Level: |Application
, lOMoAR | cPSD|
| 3013804
6. The |nurse |is |working |during |a |very |busy |night |shift, |and |the |health |care |provider |has |just |given |the |nurse |a |m
telephone, |but |the |nurse |does |not |recall |the |route. |What |is |the |best |way |for |the |nurse |to |avoid |medication |
|
a. Recopy |the |order |neatly |on |the |order |sheet, |with |the |most |common |route |indicated
b. Consult |with |the |pharmacist |for |clarification |about |the |most |common |route
c. Call |the |health |care |provider |to |clarify |the |route |of |administration
d. Withhold |the |drug |until |the |health |care |provider |visits |the |patient
ANS: |C
If |a |medication |order |does |not |include |the |route, |the |nurse |must |ask |the |health |care |provider |to |clarify |it. |Ne
|administration.
DIF: Cognitive |Level: |Application || |Cognitive |Level: |Analysis
7. Which |constitutes |the |traditional |Five |Rights |of |medication |administration?
a. Right |drug, |right |route, |right |dose, |right |time, |and |right |patient
b. Right |drug, |the |right |effect, |the |right |route, |the |right |time, |and |the |right |patient
c. Right |patient, |right |strength, |right |diagnosis, |right |drug, |and |right |route
d. Right |patient, |right |diagnosis, |right |drug, |right |route, |and |right |time
ANS: |A
The |traditional |Five |Rights |of |medication |administration |were |considered |to |be |Right |drug, |Right |route, |Rig
|Right |patient. |Right |effect, |right |strength, |and |right |diagnosis |are |not |part |of |the |traditional |Five |Rights.
DIF: Cognitive |Level: |Comprehension
8. What |correctly |describes |the |nursing |process?
a. Diagnosing, |planning, |assessing, |implementing, |and |finally |evaluating
b. Assessing, |then |diagnosing, |implementing, |and |ending |with |evaluating
c. A |linear |direction |that |begins |with |assessing |and |continues |through |diagnosing,
|planning, |and |finally |implementing
d. An |ongoing |process |that |begins |with |assessing |and |continues |with |diagnosing,
|planning, |implementing, |and |evaluating
ANS: |D
The |nursing |process |is |an |ongoing, |flexible, |adaptable, |and |adjustable |five-step |process |that |begins |with |ass
|through |diagnosing, |planning, |implementing, |and |finally |evaluating, |which |may |then |lead |back |to |any |of
DIF: Cognitive |Level: |Application
9. When |the |nurse |is |considering |the |timing |of |a |drug |dose, |which |is |most |important |to |assess?
a. The |patient’s |identification
b. The |patient’s |weight
c. The |patient’s |last |meal
d. Any |drug |or |food |allergies
ANS: |C
The |pharmacokinetic |and |pharmacodynamic |properties |of |the |drug |need |to |be |assessed |with |regard |to |any |d
|compatibility |issues. |The |patient’s |identification, |weight, |and |drug |or |food |allergies |are |not |affected |by |th
DIF: Cognitive |Level: |Application
10. The |nurse |is |writing |nursing |diagnoses |for |a |plan |of |care. |Which |reflects |the |correct |format |for |her |nursing
a. Anxiety
b. Anxiety |related |to |new |drug |therapy
c. Anxiety|related |to |anxious |feelings |about |drug |therapy, |as |evidenced |by
|statements |such |as |“I’m |upset |about |having |to |give |myself |shots”
d. Anxiety|related |to |new |drug |therapy, |as |evidenced |by |statements |such |as |“I’m
|upset |about |having |to |give |myself |shots”
ANS: |D
Formulation |of |nursing |diagnoses |is |usually |a |three-step |process. |The |only |complete |answer |is |“Anxiety |r
, lOMoAR | cPSD|
| 3013804
Chapter 02: Pharmacological Principles
| | |
Sealock: Lilley’s Pharmacology for Canadian Health Care Practice, 4th Edition
| | | | | | | | |
MULTIPLE |CHOICE
1. A |patient |is |receiving |two |different |drugs, |which, |at |their |current |dose |forms |and |dosages, |are |both |absorbed
identical |amounts. |Which |term |best |denotes |that |the |drugs |have |the |same |absorption |rates?
|
a. Equivalent
b. Synergistic
c. Compatible
d. Bioequivalent
ANS: | D
Two |drugs |absorbed |into |the |circulation |at |the |same |amount |(in |specific |dosage |forms) |have |the |same |b
|bioequivalent. |“Equivalent” |is |incorrect |because |the |term |“bioavailability” |is |used |to |express |the |extent |o
“Synergistic” |is |incorrect |because |this |term |refers |to |two |drugs |given |together |whose |resulting |effect |is
|effects |of |each |drug |given |alone. |“Compatible” |is |incorrect |because |this |term |is |a |general |term |used |to |ind
|not |have |a |chemical |reaction |when |mixed |(or |given, |in |the |case |of |drugs) |together.
DIF: Cognitive |Level: |Comprehension
2. A |patient |is |receiving |medication |via |intravenous |injection. |Which |information |should |the |nurse |provide |f
a. The |medication |will |cause |fewer |adverse |effects |when |given |intravenously.
b. The |medication |will |be |absorbed |slowly |into |the |tissues |over |time.
c. The |medication’s |action |will |begin |faster |when |given |intravenously.
d. Most |of |the |drug |is |inactivated |by |the |liver |before |it |reaches |the |target |area.
ANS: | C
Intravenous |injections |are |the |fastest |route |of |absorption. |The |intravenous |route |does |not |affect |the |num
|intravenous |route |is |not |a |slow |route |of |absorption, |and |the |intravenous |route |does |not |cause |inactivati
|before |it |reaches |the |target |area.
DIF: Cognitive |Level: |Comprehension
3. Which |is |true |regarding |parenteral |drugs?
a. They |bypass |the |first-pass |effect.
b. They |decrease |blood |flow |to |the |stomach.
c. They |are |altered |by |the |presence |of |food |in |the |stomach.
d. They |exert |their |effects |while |circulating |in |the |bloodstream.
ANS: | A
Drugs |given |by |the |parenteral |route |bypass |the |first-pass |effect, |but |they |still |must |be |absorbed |into |cells |an
|exert |their |effects. |Enteral |drugs |(drugs |taken |orally), |not |parenteral |drugs, |decrease |blood |flow |to |the |sto
|presence |of |food |in |the |stomach. |Parenteral |drugs |must |be |absorbed |into |cells |and |tissues |from |the |circula
|their |effects; |they |do |not |exert |their |effects |while |circulating |in |the |bloodstream.
DIF: Cognitive |Level: |Analysis
4. A |drug’s |half-life |is |best |defined |as
a. The |time |it |takes |for |the |drug |to |elicit |half |its |therapeutic |response.
b. The |time |it |takes |one-half |of |the |original |amount |of |a |drug |to |reach |the |target
|cells.
c. The |time |it |takes |one-half |of |the |original |amount |of |a |drug |to |be |removed |from |the
|body.
d. The |time |it |takes |one-half |of |the |original |amount |of |a |drug |to |be |absorbed |into |the
|circulation.
ANS: | C
A |drug’s |half-life |is |the |time |it |takes |for |one-half |of |the |original |amount |of |a |drug |to |be |removed |from |the |bo
